info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Cancer Biological Therapy Market Research Report Information; By Phases (Phase I, Phases II and Phases III), Type (Monoclonal Antibodies, Interferon & Interleukins, Cancer growth inhibitors, and others), End-Users (Hospitals and Clinics, Cancer Research Centers, Laboratories) - Forecast to 2030


ID: MRFR/Pharma/0123-CR | 110 Pages | Author: Kinjoll Dey| June 2017

Cancer Biological Therapy Market Overview


Market Research Future (MRFR) evaluates that the Cancer Biological Therapy Market can touch an impressive USD 82,276.8 Million by 2030. MRFR also projects that the cancer biological therapy market can attain a growth rate of 7.90% from 2022-2030 (forecast period).


Cancer Biological Therapy Market Overview


COVID-19 Analysis


The COVID-19 outbreak has temporarily paused cancer treatment across the world; however, the most affected are lung cancer patients as they are at a higher risk of the novel coronavirus. The lockdown has weakened the supply chains of several immunotherapy drugs with top vendors dealing with major manufacturing challenges. Shortage of essential raw materials following the COVID-19 pandemic could mean slower growth of the Cancer Biological Therapy Market.


Clinical trials associated with cancer immunotherapy have been interrupted by SARS-CoV-2, delaying the development of advanced cancer immunotherapy drugs and devices. The lockdown has also delayed the therapy series of a huge number of cancer patients under immunotherapy, as a result of which the cancer biological therapy market has taken a severe hit, in terms of growth.


The launch of Versavo (bevacizumab) by Dr. Reddy’s Laboratories was stated to have happened in March 2024, according to an exchange filing. This is the first biosimilar product of Dr. Reddy's to be approved and launched in the UK market. Versavo is used for treating a number of cancers, such as colorectal cancer with metastases, non-squamous advanced non-small cell lung cancer, glioblastoma recurrent after prior therapy, renal cell carcinoma with metastases, advanced cervical cancer, ovarian cancer, and metastatic breast cancer. In 2019, in countries like Thailand, Ukraine, Nepal, and Jamaica, among others, Dr Reddy launched Versavo; in India, it was sold under the trade name Persivia.


In June 2023, the National Cancer Institute (NCI) launched a major precision medicine cancer initiative that aims to establish the effectiveness of new drug combinations that target specific tumor alterations in adults and children. Named ComboMATCH or Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice, this is the largest endeavor of its kind based on testing combinations of anti-cancer agents guided by tumor biology. It exists to find out different treatments which can be advanced into more substantial clinical trials than ComboMATCH. The NCI is under the National Institutes of Health (NIH).


Poseida Therapeutics, Inc. (NASDAQ: PSTX; CEO: Mark Gergen) and Astellas Pharma Inc. (“Astellas”) strategic investment transaction was complete in August 2023 to enhance Poseida’s commitment towards revolutionizing cancer cell therapy. According to the arrangement, Astellas will make a payment of US$50 million broken down as follows: US$25 million for 8,333,333 shares of Poseida common stock at an average price of $3.00 per share, representing about 8.8% (i.e., outstanding common stock) and a one-time fee on exclusive negotiation worth $25 million for its clinical stage program P-MUC1C-ALLO1, an allogenic CAR-T cell therapy in development for multiple solid tumors indication according to the terms of this deal.


Market Dynamics


Drivers


Escalating Cancer Cases and Rising Use of Nanotechnology to Boost Growth


Significant burden of rising cancer cases and the surging death rate across the world have been major reasons for the strong growth of the cancer biological therapy market. The World Health Organization (WHO) says that cancer is one of the top five causes of death globally and claimed over 9.5 million lives in 2018 alone. Some key factors that result in cancer development can be the accelerated intake of tobacco and alcohol, which further strengthen the cancer biological therapy industry.


Researchers and vendors in the Cancer Biological Therapy Market are increasingly making use of nanotechnology to develop more innovative and effective treatment options for patient. This procedure is touted to be a game-changer for cancer diagnosis, while the advancements in materials science, as well as protein engineering, could be huge assets for medical professionals in precise targeting of cancer cells. These innovations are gaining considerable grounds backed by increasing government spending and favorable policies across developed countries.


Opportunities


Rising Education and Awareness Levels to be a Significant Opportunity


Gene therapy has emerged as a lucrative opportunity for the prominent firms in the market, considering the host of benefits compared to other traditional cancer therapies along with the rising advances in this field. The surge in biotechnological funding encouraging extensive R&D activities with respect to cancer gene therapy are expected to be significant cancer biological therapy market trends in the ensuing years.


Restraints


Huge Spending Required on Drug Development to Slow Down Growth


Requirement for substantial funds for effective drug development discourages industry participants, in turn slowing down the cancer biological therapy market growth.


Challenges


Risks Associated with Anti-Cancer Drug Therapies


In some cases, complications arise from anti-cancer drug therapies, which bring down the success rate of the overall treatment. In view of these risks, the demand for cancer biological therapy could weaken and prove to be a significant challenge over the following years.


Segment Overview


Phase III to Capture the Largest Share


The various phases in clinical trials include phase I, phases II and phases III.  Generally, the clinical trials’ success rate increases from phase I to phase II and lastly phase III, and therefore, the phase III is expected to take the lead in the cancer biological therapy market. Phase 3 clinical trials involve huge number of candidates in order to ensure the validity of the result.


Monoclonal Antibodies to Claim the Leading Position


Primary types considered in the MRFR report are interferons, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors and gene therapy. Monoclonal antibodies segment should project the highest growth in the coming years, as these have the ability to target certain proteins present on the cell surface, leading to its escalating use in cancer treatment. Also, greater preference for innovative cancer biological therapies to reduce the risk related to anti-cancer drug therapies will also mean substantial growth for the segment.


Hospitals & Clinics to be the Top End-User


Some of the key market end-users include cancer research centers and laboratories as well as hospitals & clinics. Hospitals & clinics lead the worldwide industry owing to their rising number across developing countries and the availability of a vast range of medical devices for treatment and surgeries. However, there has been striking growth in the number of cancer research centers and laboratories as well, backed by substantial funding by the government and private firms worldwide.


Regional Analysis


The US Market to Thrive as the Global Leader


In North America and globally, the US has emerged as the market leader owing to the supportive reimbursement scenario paired with the significant spending on healthcare. The US market also stands to profit from the increasing R&D investments as well as government initiatives, in addition to the extensive network of several cancer biological vaccine and drug manufacturers. Presence of effective health insurance schemes for life-threatening diseases encouraging patients to seek treatment further adds to the market value. Over the years, there has been notable progress in the US cancer gene therapy market, given the strong pipeline for the same and the growing focus of various players on the development of advanced cancer gene therapies as well as its vectors.


The European Market to be the Second Biggest Gainer


Europe is currently the second most profitable market, thanks to the high disposable income and awareness level among the mass. The significant burden of cancer, presence of a vast geriatric patient pool and the increasing advances in cancer therapies could boost business growth in the coming years. Emergence of new molecular biology techniques, advanced healthcare industry coupled with the creative approaches explored in terms of technology are also projected to benefit the European market.


The APAC Market to Soar at the Fastest Rate


Asia Pacific will most likely emerge as the fastest advancing region, considering the significant unmet needs in China and India. A few other key reasons behind the APAC market’s fast growth rate is the rise in different types of cancer cases, surge in government initiatives to raise the awareness level and the soaring number of patient assistance programs (PAPs). There has been growth in the demand for cancer biological therapy ovarian, given the mounting prevalence of ovary cancer among women. Expanding aging population, surge in environmental pollution, and unhealthy eating habits seems to be the top causes of ovary cancer in the region, which bolsters the demand for cancer biological therapy.


Competitive Landscape


Players Spend Considerably on R&D Activities as Cancer Cases Escalate


Cancer has been the top reason for deaths worldwide, and in view of the escalating cases of different types of cancer, firms have been focused on spending considerably on R&D activities to produce technically innovative devices with multiple applications. Moreover, industry vendors also implement several competitive initiatives like acquisition, mergers and partnerships to strengthen their positions, which also results in biologic therapy market growth.


Amgen has been a well-known name in the cancer biological therapy industry, known for its commitment to the relentless focus on achieving breakthroughs for different cancer cases. The company boasts of a diverse and extensive range of advanced therapeutic approaches that facilitate successful outcomes.


List of Key Companies Covered in this Report




    • Amgen Inc.





    • Bristol-Myers Squibb





    • Celgene Corporation





    • ELI Lilly and Company





    • Hoffmann-La Roche AG





    • EnGeneIC Ltd





    • Merck & Co. Inc.





    • Novartis, Pfizer Inc.



Recent Developments




    • December 2020 – Novartis recently updated its median overall survival outcome for Kisqali combined with endocrine therapy for premenopausal women with HR+HER2- metastatic breast cancer. The study has analyzed Kisqali in combination with endocrine therapy as the key biological therapy for breast cancer as viable treatment compared to only the endocrine therapy in women with breast cancer.





    • December 2020 – Bayer has entered an agreement with Atara Biotherapeutics Inc. for development and production tie up for mesothelin-directed CAR T-cell as the biological therapy for lung cancer. The agreement involves developing ATA3271, an allogeneic armored T-cell immunotherapy and ATA2271, an autologous version for strong mesothelin-expressing tumors like non-small-cell lung cancer.



Report Overview


MRFR has mentioned the base year, appraisal period and the market value expected during the given period. The market study also focuses on a few major developments following the COVID-19 outbreak. In addition to the easy to understand segmentation, the report also anticipates the future size along with the historical value, coupled with technological innovations, and the key growth rendering factors. Moreover, some of the eminent players and the strategies they generally adopt are also listed in the report.


Segmentation Table


By Phase




    • Phase I





    • Phase II





    • Phase III



By Type




    • Monoclonal Antibodies





    • Interferon’s





    • Interleukins





    • Cancer Growth Inhibitors





    • Gene Therapy





    • Colony-Stimulating Factors



By End-Users




    • Hospitals and Clinics

    • Cancer Research Centers 

    • Laboratories


Report Attribute/Metric Details
  Market Size    USD 82,276.8 Million
  CAGR   7.90%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Phases, Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, Hoffmann-La Roche AG, EnGeneIC Ltd, Merck & Co. Inc., Novartis, Pfizer Inc.
  Key Market Opportunities   Rising Education and Awareness Levels to be a Significant Opportunity
  Key Market Drivers   Escalating Cancer Cases and Rising Use of Nanotechnology to Boost Growth


Frequently Asked Questions (FAQ) :

cancer biological therapy market valuation can touch USD 82,276.8 million by 2030.

cancer biological therapy market can expand at 7.90% CAGR from 2022-2030.

Demand for advanced therapies, growth of cancer healthcare, and rise in cancer survival rates are major drivers of the global cancer biological therapy market.

High costs of treatments and its adverse effects are restraining factors of the global cancer biological therapy market.

Amgen Inc., Celgene Corporation, F. Hoffmann-La Roche AG, Novartis, Pfizer Inc., EnGeneIC Ltd, ELI Lilly and Company, Merck & Co., Inc., and Bristol-Myers Squibb are prominent players of the global cancer biological therapy market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.